Exploratory study on the individualized application of eltrombopag in paediatric immune thrombocytopenia guided by therapeutic drug monitoring

Documenti analoghi

• The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China
  di: Yu Hu, et al.
  Pubblicazione: (2024)
• Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China
  di: Zhifa Wang, et al.
  Pubblicazione: (2024)
• Is there a role for eltrombopag drug levels in paediatric immune thrombocytopenia management?
  di: Clara Lo
  Pubblicazione: (2024)
• Urine proteomics uncovers biomarker candidates for early identifying rituximab beneficiaries in paediatric steroid‐resistant immune thrombocytopenia
  di: Yuncui Yu, et al.
  Pubblicazione: (2025)
• Interplay of leucocyte–platelet complexes and clinical response to eltrombopag in immune thrombocytopenia patients
  di: Rubén Osuna‐Gómez, et al.
  Pubblicazione: (2024)